KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evolent Health (EVH) Common Equity (2016 - 2025)

Historic Common Equity for Evolent Health (EVH) over the last 12 years, with Q3 2025 value amounting to $842.2 million.

  • Evolent Health's Common Equity fell 1891.35% to $842.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $842.2 million, marking a year-over-year decrease of 1891.35%. This contributed to the annual value of $1.0 billion for FY2024, which is 622.29% down from last year.
  • According to the latest figures from Q3 2025, Evolent Health's Common Equity is $842.2 million, which was down 1891.35% from $896.0 million recorded in Q2 2025.
  • Over the past 5 years, Evolent Health's Common Equity peaked at $1.1 billion during Q1 2023, and registered a low of $607.5 million during Q3 2021.
  • Moreover, its 5-year median value for Common Equity was $896.0 million (2025), whereas its average is $877.2 million.
  • In the last 5 years, Evolent Health's Common Equity plummeted by 2712.57% in 2021 and then skyrocketed by 8352.85% in 2023.
  • Evolent Health's Common Equity (Quarter) stood at $693.6 million in 2021, then increased by 23.9% to $859.4 million in 2022, then grew by 24.24% to $1.1 billion in 2023, then fell by 6.22% to $1.0 billion in 2024, then fell by 15.88% to $842.2 million in 2025.
  • Its Common Equity stands at $842.2 million for Q3 2025, versus $896.0 million for Q2 2025 and $935.5 million for Q1 2025.